Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease.

IF 3.2 Q2 ONCOLOGY
JCO Global Oncology Pub Date : 2025-04-01 Epub Date: 2025-04-18 DOI:10.1200/GO-24-00500
Nguyen-Son Le, Asli Zeybek, Klaus Hackner, Cornelia Gallauner, Josef Singer, Felix Schragel, Petra Georg, Sandra Gottsauner-Wolf, Martin Pecherstorfer, Gudrun Kreye
{"title":"Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease.","authors":"Nguyen-Son Le, Asli Zeybek, Klaus Hackner, Cornelia Gallauner, Josef Singer, Felix Schragel, Petra Georg, Sandra Gottsauner-Wolf, Martin Pecherstorfer, Gudrun Kreye","doi":"10.1200/GO-24-00500","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Palliative radiotherapy (PRT) toward the end of life (EOL) in advanced tumor disease is contentious. Although EOL RT can alleviate cancer-related symptoms, relief typically occurs weeks to months after treatment, potentially compromising the quality of life of patients during the final stages. This study aims to assess factors influencing the decision-making process regarding EOL RT.</p><p><strong>Materials and methods: </strong>This retrospective study of a real-world cohort included 684 consecutive patients with a diagnosis of a solid tumor who died between 2017 and 2021. In these patients, factors potentially influencing the administration of EOL RT were analyzed.</p><p><strong>Results: </strong>Of the 684 patients, 164 received PRT, with 60 (36.6%) receiving EOL RT within the last 30 days of life. The median time from the last RT session to death was 55 days. Significant factors influencing EOL RT administration were age ≤65 years (odds ratio [OR], 1.75 [95% CI, 1.02 to 3.01]), Union for International Cancer Control stage IV (OR, 2.77 [95% CI, 1.41 to 5.46]), lung cancer (OR, 2.16 [95% CI, 1.00 to 4.68]), palliative care referral (OR, 1.80 [95% CI, 0.98 to 3.30]), systemic anticancer treatment ≤30 days before death (OR, 1.87 [95% CI, 1.05 to 3.33]), and Eastern Cooperative Oncology Group performance status ≥2 (OR, 3.73 [95% CI, 1.88 to 7.40]). Furthermore, RT near the EOL was more likely administered at multiple sites (OR, 2.08 [95% CI, 1.00 to 4.29]) and with ≤5 fractions (OR, 2.37 [95% CI, 1.23 to 4.57]), while being associated with lower response rates (OR, 0.43 [95% CI, 0.21 to 0.86]) and increased therapy discontinuation (OR, 4.40 [95% CI, 1.45 to 13.37]).</p><p><strong>Conclusion: </strong>These findings highlight varying RT patterns influenced by specific factors, demonstrating the complexity of EOL treatment decisions in advanced cancer care. Identifying key factors for personalized, patient-centered EOL RT decisions warrants further investigation.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400500"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-24-00500","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Palliative radiotherapy (PRT) toward the end of life (EOL) in advanced tumor disease is contentious. Although EOL RT can alleviate cancer-related symptoms, relief typically occurs weeks to months after treatment, potentially compromising the quality of life of patients during the final stages. This study aims to assess factors influencing the decision-making process regarding EOL RT.

Materials and methods: This retrospective study of a real-world cohort included 684 consecutive patients with a diagnosis of a solid tumor who died between 2017 and 2021. In these patients, factors potentially influencing the administration of EOL RT were analyzed.

Results: Of the 684 patients, 164 received PRT, with 60 (36.6%) receiving EOL RT within the last 30 days of life. The median time from the last RT session to death was 55 days. Significant factors influencing EOL RT administration were age ≤65 years (odds ratio [OR], 1.75 [95% CI, 1.02 to 3.01]), Union for International Cancer Control stage IV (OR, 2.77 [95% CI, 1.41 to 5.46]), lung cancer (OR, 2.16 [95% CI, 1.00 to 4.68]), palliative care referral (OR, 1.80 [95% CI, 0.98 to 3.30]), systemic anticancer treatment ≤30 days before death (OR, 1.87 [95% CI, 1.05 to 3.33]), and Eastern Cooperative Oncology Group performance status ≥2 (OR, 3.73 [95% CI, 1.88 to 7.40]). Furthermore, RT near the EOL was more likely administered at multiple sites (OR, 2.08 [95% CI, 1.00 to 4.29]) and with ≤5 fractions (OR, 2.37 [95% CI, 1.23 to 4.57]), while being associated with lower response rates (OR, 0.43 [95% CI, 0.21 to 0.86]) and increased therapy discontinuation (OR, 4.40 [95% CI, 1.45 to 13.37]).

Conclusion: These findings highlight varying RT patterns influenced by specific factors, demonstrating the complexity of EOL treatment decisions in advanced cancer care. Identifying key factors for personalized, patient-centered EOL RT decisions warrants further investigation.

临终前姑息性放疗:影响晚期肿瘤患者放疗的因素分析。
目的:晚期肿瘤患者临终前姑息放疗(PRT)存在争议。虽然EOL RT可以缓解癌症相关症状,但缓解通常发生在治疗后几周到几个月,这可能会影响患者在最后阶段的生活质量。本研究旨在评估影响EOL rt决策过程的因素。材料和方法:本研究对现实世界队列进行了回顾性研究,包括684名在2017年至2021年间连续死亡的确诊为实体瘤的患者。在这些患者中,分析了可能影响EOL RT给药的因素。结果:684例患者中,164例接受了PRT治疗,其中60例(36.6%)在生命的最后30天内接受了EOL RT治疗。从最后一次RT到死亡的中位时间为55天。重要影响因素EOL RT政府在年龄≤65岁(比值比(或),1.75(95%可信区间,1.02 - 3.01)),国际癌症控制联盟第四阶段(或者,2.77(95%可信区间,1.41 - 5.46)),肺癌(或者,2.16(95%可信区间,1.00 - 4.68)),缓和医疗转诊(或者,1.80(95%可信区间,0.98 - 3.30)),系统性抗癌治疗前≤30天死亡(或者,1.87(95%可信区间,1.05 - 3.33)),和东部合作肿瘤组性能状态≥2(或者,3.73(95%可信区间,1.88 - 7.40))。此外,靠近EOL的RT更有可能在多个部位(OR, 2.08 [95% CI, 1.00至4.29])和≤5个部位(OR, 2.37 [95% CI, 1.23至4.57])进行,同时与较低的缓解率(OR, 0.43 [95% CI, 0.21至0.86])和增加的治疗中断(OR, 4.40 [95% CI, 1.45至13.37])相关。结论:这些发现突出了受特定因素影响的不同RT模式,表明了晚期癌症治疗中EOL治疗决策的复杂性。确定个性化、以患者为中心的EOL RT决策的关键因素值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信